Archive: November 2022
Feature Article
Ongoing Progress in BRAF-Mutated Non–Small Cell Lung Cancer
Abstract: Activating BRAF mutations are detected in 1.5% to 4.5% of patients with non–small cell lung cancer (NSCLC). These mutations involve the mitogen-activated protein kinase/extracellular signal-regulated […]
Feature Article
The Role of Cytoreductive Surgery and Intraperitoneal Chemotherapy in Gastric Cancer
Abstract: Gastric cancer (GC) with peritoneal carcinomatosis (PC) progresses rapidly and has historically dismal survival rates. Given the aggressive tumor biology and poor survival outcomes of […]
Prostate Cancer In Focus
The Use of AI to Identify Predictive, Pathology-Based Biomarkers in Men With Prostate Cancer
H&O How is artificial intelligence (AI) defined in the context of cancer biomarkers, including predictive biomarkers? DS AI is a very general term, of course, that […]
Lung Cancer in Focus
Advances in Immune Checkpoint Inhibition for Patients With Lung Cancer
H&O What are the newest indications for checkpoint inhibitors in lung cancer? HB The newest indication in the neoadjuvant setting is the use of nivolumab (Opdivo, […]
Advances in LLM
Key Points From the SHINE Trial in Mantle Cell Lymphoma
H&O Could you provide some background on mantle cell lymphoma? JT Mantle cell lymphoma is an uncommon type of lymphoma. It represents approximately 6% of non-Hodgkin […]
Letter From the Editor
Letter From the Editor: Computational Faith
I have always had great reverence for our colleagues in biostatistics. Whether my reverence derives from the limitations of my own statistical training or from the […]
Advances in Drug Development
Serving on the FDA Oncologic Drugs Advisory Committee
H&O What is the role of the Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug Administration (FDA)? PH ODAC is one of several […]